Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 4/20 | 1.00 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.68 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.56 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.56 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.56 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.56 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Norlevorphanol SCHEMBL13383458 | 1.00 | SIGMAR1 (1.00) | SIGMAR1SLC22A1GRIN1GRIN2ACYP2D6 | |
| Norlevorphanol SCHEMBL29851122 | 1.00 | SIGMAR1 (1.00) | SIGMAR1SLC22A1GRIN1GRIN2ACYP2D6 | |
| Norlevorphanol SCHEMBL4759025 | 1.00 | SIGMAR1 (1.00) | SIGMAR1SLC22A1GRIN1GRIN2ACYP2D6 | |
| Norlevorphanol SCHEMBL23823 | 1.00 | SIGMAR1 (1.00) | SIGMAR1SLC22A1GRIN1GRIN2ACYP2D6 | |
| Norlevorphanol SCHEMBL23822 | 1.00 | SIGMAR1 (1.00) | SIGMAR1SLC22A1GRIN1GRIN2ACYP2D6 | |
| Norlevorphanol SCHEMBL6900806 | 1.00 | SIGMAR1 (1.00) | SIGMAR1SLC22A1GRIN1GRIN2ACYP2D6 | |
| Norlevorphanol SCHEMBL18920299 | 1.00 | SIGMAR1 (1.00) | SIGMAR1SLC22A1GRIN1GRIN2ACYP2D6 | |
| Norlevorphanol SCHEMBL21095579 | 1.00 | SIGMAR1 (1.00) | SIGMAR1SLC22A1GRIN1GRIN2ACYP2D6 | |
| Norlevorphanol SCHEMBL20808855 | 1.00 | SIGMAR1 (1.00) | SIGMAR1SLC22A1GRIN1GRIN2ACYP2D6 | |
| Norlevorphanol SCHEMBL14743778 | 1.00 | SIGMAR1 (1.00) | SIGMAR1SLC22A1GRIN1GRIN2ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3383851-B1 | DEXTRORPHAN-DERIVATIVES WITH SUPPRESSED CENTRAL NERVOUS ACTIVITY | HEINRICH HEINE UNIV DUESSELDORF (DE) | 2021-07-14 | — | — | EP | disclosed |
| US-10464904-B2 | Dextrorphan-derivatives with suppressed central nervous activity | HEINRICH-HEINE-UNIVERSITAT DUSSELDORF (DE) | 2019-11-05 | — | — | US | disclosed |
| US-20180362469-A1 | DEXTRORPHAN-DERIVATIVES WITH SUPPRESSED CENTRAL NERVOUS ACTIVITY | HEINRICH-HEINE-UNIVERSITAT DUSSELDORF (DE) | 2018-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10464904-B2 | Dextrorphan-derivatives with suppressed central nervous activity | BDNF, NR1D1, NR1D2 | SIGMAR1 726/4885SLC22A1 1301/4885GRIN1 13/4885 |
| US-20180362469-A1 | DEXTRORPHAN-DERIVATIVES WITH SUPPRESSED CENTRAL NERVOUS ACTIVITY | BDNF, NR1D1, NR1D2 | SIGMAR1 726/4885SLC22A1 1301/4885GRIN1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.